首页> 美国卫生研究院文献>Oncotarget >Combination of specific allergen and probiotics induces specific regulatory B cells and enhances specific immunotherapy effect on allergic rhinitis
【2h】

Combination of specific allergen and probiotics induces specific regulatory B cells and enhances specific immunotherapy effect on allergic rhinitis

机译:特定变应原和益生菌的组合可诱导特定的调节性B细胞并增强对变应性鼻炎的特异性免疫治疗作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The therapeutic efficacy of allergen specific immunotherapy (SIT) on allergic diseases is to be improved. Probiotics can regulate immune response. This study aims to promote the effect of SIT on allergic rhinitis (AR) by co-administration with Clostridium butyricum (Cb). In this study, patients with AR sensitized to mite allergens were enrolled to this study, and treated with SIT or/and Cb. The therapeutic efficacy was evaluated by the total nasal symptom scores (NSS), medication scores, serum specific IgE levels and T helper (Th)2 cytokine levels. The improvement of immune regulation in the AR patients was assessed by immunologic approaches. The results showed that treating AR patients with SIT alone markedly reduced NSS and medication scores; but did not alter the serum specific IgE, Th2 cytokines and skin prick test (SPT) index. The clinical symptoms on AR in SIT group relapsed one month after stopping SIT. Co-administration of Cb significantly enhanced the efficacy of SIT on AR as shown by suppression of NSS, medication scores, serum specific IgE, Th2 cytokines and SPT index; the regulatory B cell frequency was also markedly increased. Such an effect on AR was maintained throughout the observation period even after stopping the treatment. Butyrate blocked the activation of histone deacetylase-1, the downstream activities of epsilon chain promoter activation, and the IgE production in the antigen specific B cells. On the other hand, butyrate induced the IL-10 expression in B cells with a premise of the B cell receptor activation by specific antigens. In conclusion, administration with Cb can markedly enhance the efficacy of SIT on AR.
机译:过敏原特异性免疫疗法(SIT)对过敏性疾病的治疗功效有待提高。益生菌可以调节免疫反应。这项研究旨在通过与丁酸梭菌(Cb)共同使用来增强SIT对变应性鼻炎(AR)的作用。在这项研究中,对螨过敏原致敏的AR患者入选本研究,并接受SIT或/和Cb治疗。通过总鼻症状评分(NSS),药物评分,血清特异性IgE水平和T辅助(Th)2细胞因子水平评估疗效。通过免疫学方法评估了AR患者的免疫调节水平。结果表明,单独使用SIT治疗AR患者可显着降低NSS和用药得分;但没有改变血清特异性IgE,Th2细胞因子和皮肤点刺试验(SPT)指数。停药后1个月,SIT组AR的临床症状复发。如抑制NSS,药物评分,血清特异性IgE,Th2细胞因子和SPT指数所示,Cb的共同给药可显着增强SIT对AR的疗效。调节性B细胞频率也明显增加。即使在停止治疗后,在整个观察期内仍保持这种对AR的作用。丁酸盐可阻止组蛋白脱乙酰基酶-1的激活,ε链启动子激活的下游活性以及抗原特异性B细胞中IgE的产生。另一方面,丁酸酯以特定抗原激活B细胞受体为前提,诱导B细胞中IL-10表达。总之,用Cb给药可以显着增强SIT对AR的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号